Area of research
Genetics · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Glioma Diagnosis and Treatment, Advanced MRI Techniques and Applications, Acute Ischemic Stroke Management, and MRI in cancer diagnosis.
Toward Noninvasive High‐Resolution In Vivo pH Mapping in Brain Tumors by <sup>31</sup>P‐Informed deepCEST MRI
Pathological tissue changes in brain tumors affect the pH‐sensitivity of the T1‐corrected apparent exchange dependent relaxation (AREX) of the amide protons
Glioma-associated tertiary lymphoid structures are sites of lymphocyte clonal expansion and plasma cell formation
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma
Longitudinal study on MRI and neuropathological findings: Neither DSC-perfusion derived rCBVmax nor vessel densities correlate between newly diagnosed and progressive glioblastoma
Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression
The Acute Superficial Siderosis Syndrome — Clinical Entity, Imaging Findings, and Histopathology
Topographic Mapping of Isolated Thalamic Infarcts Using Vascular and Novel Probabilistic Functional Thalamic Landmarks
A Paravermal Trans-Cerebellar Approach to the Posterior Fossa Tumor Causes Hypertrophic Olivary Degeneration by Dentate Nucleus Injury
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes
Longitudinal, leakage corrected and uncorrected rCBV during the first-line treatment of glioblastoma: a prospective study
Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study
P06.05 Myoinositol as a predictive baseline biomarker for overall survival of patients with recurrent glioblastoma treated with Bevacizumab: A 1H-magnetic resonance spectroscopy study.